Premium
Surgical treatment of the neck in patients with salivary gland carcinoma
Author(s) -
WestergaardNielsen Marie,
Godballe Christian,
Grau Eriksen Jesper,
Larsen Stine Rosenkilde,
Kiss Katalin,
Agander Tina,
Parm Ulhøi Benedicte,
Charabi Birgitte,
Ehlers Klug Tejs,
Jacobsen Henrik,
Johansen Jørgen,
Kristensen Claus Andrup,
Andersen Elo,
Andersen Maria,
Bjørndal Kristine
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26667
Subject(s) - medicine , occult , salivary gland , neck dissection , histology , salivary gland cancer , carcinoma , stage (stratigraphy) , submandibular gland , dissection (medical) , pathology , oncology , surgery , paleontology , alternative medicine , biology
Abstract Background Elective neck dissection (END) in patients with salivary gland carcinoma is controversial and there are no universally accepted guidelines. Methods Patients were identified from the Danish Head and Neck Cancer Group. Between 2006 and 2015, 259 patients with primary salivary gland carcinoma were treated with END. Variables potentially associated with regional metastases were analyzed using logistic regression. Neck recurrence‐free survival was calculated using the Kaplan–Meier method. Results Occult metastases were found in 36 of the patients treated with END (14%) and were particularly frequent among patients with T3/T4 tumors and high‐grade histology tumors. In multivariate analyses, high‐grade histology and vascular invasion were associated with occult metastases. Conclusion We recommend END of levels II and III for patients with high‐grade or unknown histological grade tumors, and for T3/T4 tumors. Levels I, II, and III should be included in END in patients with submandibular, sublingual, or minor salivary gland carcinomas.